UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT _______)*
LIGHTTOUCH VEIN & LASER, INC.
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
(Title of Class of Securities)
532264 20 7
(CUSIP Number)
FAY M. MATSUKAGE, ESQ., 455 SHERMAN STREET, SUITE 300, DENVER, CO 80203,
303-777-3737
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
June 8, 2000
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
[ ].
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
CUSIP NO. 532264 20 7 PAGE 2 OF 4
SCHEDULE 13D
1 NAME OF REPORTING PERSON JOHN L. BUKER
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (Entities Only)
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(See Instructions) (b) [ ]
3 SEC USE ONLY
4 SOURCE OF FUNDS (See Instructions)
OO
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) [ ]
6 CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES
NUMBER OF 7 SOLE VOTING POWER
SHARES BENE- 750,000 SHARES
FICIALLY 8 SHARED VOTING POWER
OWNED BY 250,000
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 750,000 SHARES
PERSON WITH 10 SHARED DISPOSITIVE POWER
250,000
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,000,000 SHARES
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES (See Instructions) [ ]
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.96 %
14 TYPE OF REPORTING PERSON*
IN
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 2 OF 4
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATESTATION.
<PAGE>
CUSIP NO. 532264 20 7 PAGE 3 OF 4
ITEM. 1 SECURITY AND ISSUER.
The class of equity securities to which this Schedule 13D relates is the Common
Stock, $.001 par value, of LightTouch Vein & Laser, Inc., a Nevada corporation
(the "Issuer"). Its principal executive offices are located at 10663 Montgomery
Road, Cincinnati, Ohio 45242.
ITEM 2. IDENTITY AND BACKGROUND.
The person filing this statement is Dr. John L. Buker, M.D. Dr. Buker is a
United States citizen. The business address of Dr. Buker is 880 Lexington Drive,
Suite 200, Lexington, KY 40503. Dr. Buker's principal occupation is as Medical
Director of LightTouch Vein & Laser of Lexington, Inc.
During the past five years Dr. Buker has not been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors).
During the past five years Dr. Buker has not been a party to a civil proceeding
of a judicial or administrative body as a result of which a judgment, decree, or
final order has been issued enjoining future violations of, or prohibiting or
mandating activities subject to, United States federal or state securities laws
or finding any violation with respect to such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
Pursuant to the terms of the acquisition of Dr. Buker's practices by the Issuer,
Dr. Buker and his wife were issued 1,000,000 shares of the Issuer's Common Stock
as consideration for the practices. In addition, the Issuer issued a promissory
note to Dr. John L. Buker and his wife in the amount of $1,000,000.
ITEM 4. PURPOSE OF TRANSACTION.
Dr. Buker and his wife acquired 1,000,000 shares of Common Stock of the Issuer
as consideration for the purchase of his practices described in Item 3 above.
Dr. Buker does not have any other present plans or proposals which relate to or
would result in:
(1) a sale or transfer of a material amount of assets of the Issuer or
any subsidiary thereof;
(2) any material change in the present capitalization or divided
policy of the Issuer;
(3) changes in the Issuer's charter or bylaws or other actions which
may impede the acquisition of control of the Issuer by any person;
(4) causing a class of securities of the Issuer to be delisted from a
national securities exchange or to cease to be authorized to be
quoted on NASDAQ;
(5) a class of equity securities of the Issuer becoming eligible for
termination of registration pursuant to Section 12(g)(4) of the
Securities Exchange Act; or
(6) any action similar to any of those enumerated above.
<PAGE>
CUSIP NO. 532264 20 7 PAGE 4 OF 4
Notwithstanding the foregoing, Dr. Buker will continue to review his investment
in the Issuer and reserves the right to change his intention with respect to any
or all of such matters.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) As of June 8, 2000, Dr. Buker owned of record 750,000 shares and
his wife, Patricia Buker, owned of record 250,000 shares for a
total of 1,000,000 shares (10.96%) of the Issuer's Common Stock
(b) As of June 8, 2000, Dr. Buker had the sole power to vote and
dispose of 750,000 shares and shared power to vote and dispose of
the 250,000 shares held of record by his wife.
(c) During the sixty-day period preceding the filing of this Schedule
13D, Dr. Buker did not have any transactions in the stock of the
Issuer, other than those described above in Item 3 and Item 4.
(d) No other person is known to have the right to receive or the power
to direct the receipt of dividends from, or the proceeds from the
sale of, shares owned by Dr. Buker.
(e) Dr. Buker continues to be the beneficial owner of more than five
percent of the outstanding common stock of the Issuer.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to
Securities of the Issuer.
None.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
None.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
/s/ JOHN L. BUKER, M.D.
Date: July 19, 2000 --------------------------------------
John L. Buker, M.D.
